Phase 2 N=5 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Retinal Disease
Primary: Change in Visual Acuity at Month 3 Compared to Baseline. — 0 ETDRS letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 H1N1 Vaccine in Pregnant Women
Influenza
Primary: Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination — 15; 21; 26; 37 Participants
Phase 2 N=199 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Colorectal Cancer
Primary: Disease Control Rate (DCR) and Objective Response Rate (ORR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) — 31.0; 32.4; 0; 0 Percentage of…
Phase 2 N=200 Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Acute Gout
Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…
Phase 2 N=112 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Phase 2 N=4 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
Multiple Myeloma
Primary: Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. — 0 participant response
Phase 2 N=51 Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Advanced Cancer
Primary: Number of Participants With Clinically Meaningful Prolongation of the QT Interval Corrected for Heart Rate (QTc) From Time-matched Baseline — 0 Participants
Phase 2 N=421 A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
Neuropathy, Diabetic
Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data…
Phase 2 N=805 Sanofi H1N1 + TIV - Adults and Elderly
Influenza
Primary: Number of Participants Age 18 to 64 Years With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the H1N1 2009 Virus 21 Days…
Phase 2 N=24 ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Spirometry Parameter: Peak Forced Expiratory Volume in 1 Second(FEV1)in Liters (L) — 1.707; 1.696; 1.672; 1.676 Liters — p=<0.0001
Phase 2 N=184 Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
Anemia · Hemosiderosis
Primary: The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths — 85; 99; 36; 50 Participants
Phase 2 N=183 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
Systemic Lupus Erythematosus
Primary: Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare — 94; 47 Participants
Phase 2 N=154 Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response at Week 16 — 17.6; 9.6; 3.9 percentage of participants — p=0.022
Phase 2 N=39 A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
Hypertension
Primary: Maximum Plasma Concentration (Cmax) at Day 1 and Day 8 in 6-11 and 12-17 Year Old Patients — 76.8; 393.3; 82.2; 397.1 ng/ml
Phase 2 N=95 Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Response — 5; 49; 0; 4 Participants